Literature DB >> 22359740

Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism.

Karin Srulijes1, Matthias Reimold, Rajka M Liscic, Sarah Bauer, Elisabeth Dietzel, Inga Liepelt-Scarfone, Daniela Berg, Walter Maetzler.   

Abstract

BACKGROUND: We hypothesized that postural instability and cognitive decline in patients with Richardson’s syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism.
METHODS: Eleven patients with Richardson’s syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson’s disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET).
RESULTS: Richardson’s syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson’s syndrome (area under the curve 5 0.86) and from Parkinson’s disease (area under the curve 5 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson’s syndrome patients.
CONCLUSIONS: Richardson’s syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease showed different metabolic patterns in fluorodeoxyglucose PET.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22359740     DOI: 10.1002/mds.23975

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

Review 2.  "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Authors:  Ján Necpál; Miroslav Borsek; Bibiána Jeleňová
Journal:  Neurol Sci       Date:  2021-09-17       Impact factor: 3.307

3.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

Review 4.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

Review 5.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

Review 6.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-28       Impact factor: 9.236

7.  Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy.

Authors:  Yulia Surova; Markus Nilsson; Jimmy Lätt; Björn Lampinen; Olof Lindberg; Sara Hall; Håkan Widner; Christer Nilsson; Danielle van Westen; Oskar Hansson
Journal:  Neuroradiology       Date:  2015-08-08       Impact factor: 2.804

Review 8.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.